Emerald Medical Applications Corp. (OTCMKTS:MRLA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On April 4, 2017, the Board of Directors of Emerald Medical
Applications Corp. (the Registrant) appointed Mr. Alimi Ahmed,
who had been serving as a director of the Registrant since
December 25, 2016, as Chairman of the Board of Directors,
replacing Mr. Yair Fudim, who had served as Chairman since April
30, 2015. Mr. Fudim will continue to serve as a Director.

Alimi Ahmed, age 47, who has served on the Registrant’s Board
since December 30, 2016, as the Registrant’s new CEO. Mr. Ahmed,
is highly-accomplished investor who has served in management of
several early-stage medical companies, including his current
position as Chairman and CEO of VaxilBio Ltd, an Israeli-based
company founded by scientists from the Weizmann Institute,
Israel’s top research university, to provide new approaches to
immunotherapy. Mr. Ahmed is also an investor of Therapix
Biosciences Ltd (Therapix Bio). On March 21, 2017, the SEC
declared Therapix Bio’s registration statement on Form F-1
effective, successfully registering 2,000,000 American Depositary
Shares, or ADSs, which are listed on the NASDAQ (NASDAQ: TRPX0
and on the Tel-Aviv Stock Exchange (TASE: THXBY), atthe public
offering priceof $6.00 per ADS, which offering was underwritten
by Laidlaw Company (UK) Ltd.

Mrs. Adi Zamir, the Registrant’s CEO, submitted a letter to the
Board of Directors on March 26, 2017,announcing that to the terms
of her employment agreement, she would resign as the
Registrant’s CEO effective on June 23, 2017 (the Effective
Date). During the period from March 26, 2017 until the Effective
Date, Mrs. Zamir stated that she will continue to serve as CEO
and further stated that if the Registrant appoints a successor
CEO prior to the Effective Date, Mrs. Zamir agreed to continue to
serve the Registrant in a non-executive officer capacity until
the Effective Date.

The Registrant’s Board of Directors accepted the letter of
resignation and is most appreciative of the professional services
and diligence exhibited by Mrs. Zamir in the performance of her
duties as CEO to date and through June 23, 2017. The letter of
resignation dated March 26, 2017 is attached as an Exhibit 17.7
hereto.

Item 9.01 Financial Statements and Exhibits.

(a) The following documents are filed as exhibits to this report
on Form 8-K or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical
reference to the SEC filing that included such document.

About Emerald Medical Applications Corp. (OTCMKTS:MRLA)

Emerald Medical Applications Corp. operates through its subsidiary, Emerald Medical Applications Ltd. (Emerald), which is a digital health company. Emerald is engaged in the development, sale and service of imaging solutions utilizing its DermaCompare software that it developed for use in derma imaging and analytics. Emerald’s DermaCompare solution allows dermatologists and other medical care professionals, using a set of total body photography (TBP), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smartphones or tablets. DermaCompare imaging solution is provided as a software platform for early detection of Melanoma for classification of dermatological lesions as published by the National Institute of Health (NIH) for analysis of moles. DermaCompare imaging software solution reads and extracts data from those images and in essence turns digital camera, camera-equipped smartphones and tablets into virtual scanning devices.

Emerald Medical Applications Corp. (OTCMKTS:MRLA) Recent Trading Information

Emerald Medical Applications Corp. (OTCMKTS:MRLA) closed its last trading session down -0.010 at 0.250 with 1,390 shares trading hands.